Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Shen yang
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
75High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07407140CT.gov VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML | — | Not Yet Recruiting | — | — | — |
NCT07255872CT.gov A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia | — | Not Yet Recruiting | — | — | — |
NCT07651176CT.gov Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy | — | Enrolling By Invitation | — | — | — |
NCT07651163CT.gov Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy | — | Enrolling By Invitation | — | — | — |
NCT07223814CT.gov Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML) | — | Recruiting | — | — | — |
NCT07228273CT.gov Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT06770257CT.gov Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy | — | Withdrawn | — | — | — |
NCT07211958CT.gov Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation | — | Recruiting | — | — | — |
NCT07007312CT.gov Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | — | Recruiting | — | — | — |
NCT07132684CT.gov Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients | — | Recruiting | — | — | — |
Show 117 more trialsShow fewer
NCT07108530CT.gov Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study | — | Recruiting | — | — | — |
NCT07078591CT.gov Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML | — | Recruiting | — | — | — |
NCT06697327CT.gov Daunorubicin + Cytarabine + Venetoclax in de Novo AML | — | Enrolling By Invitation | — | — | — |
NCT06744556CT.gov HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML | — | Active Not Recruiting | — | — | — |
NCT06744504CT.gov Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 | — | Recruiting | — | — | — |
NCT06810791CT.gov HVA vs IA/DA or VA in the Treatment of ND HR-AML | — | Recruiting | — | — | — |
NCT06313437CT.gov Revumenib in Combination With 7+3 + Midostaurin in AML | — | Recruiting | — | — | — |
NCT07514936CT.gov Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia | — | Recruiting | — | — | — |
NCT06497062CT.gov Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT06635681CT.gov Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML | — | Recruiting | — | — | — |
NCT05554406CT.gov Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | — | Recruiting | — | — | — |
NCT05554393CT.gov Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) | — | Recruiting | — | — | — |
NCT06529250CT.gov Intermediate-dose HAD Regimen for CEBPA Double-mutated AML | — | Recruiting | — | — | — |
NCT05886049CT.gov A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease | — | Recruiting | — | — | — |
NCT05564390CT.gov MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | — | Recruiting | — | — | — |
NCT07131059CT.gov MRD-positive AML Clinical Study | — | Recruiting | — | — | — |
NCT06928376CT.gov A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients | — | Recruiting | — | — | — |
NCT05904106CT.gov Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML | — | Recruiting | — | — | — |
NCT05939180CT.gov VA vs DA for Newly Diagnosed Hig-risk AML | — | Recruiting | — | — | — |
NCT05829434CT.gov Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS | — | Withdrawn | — | — | — |
NCT06345365CT.gov MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | — | Recruiting | — | — | — |
NCT06182592CT.gov A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia | — | Not Yet Recruiting | — | — | — |
NCT05801835CT.gov A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection | — | Unknown | — | — | — |
NCT05955261CT.gov A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia | — | Suspended | — | — | — |
NCT05735184CT.gov A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | — | Recruiting | — | — | — |
NCT06068621CT.gov Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT05726110CT.gov Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT05453903CT.gov A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies | — | Active Not Recruiting | — | — | — |
NCT04628026CT.gov Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 | — | Recruiting | — | — | — |
NCT05361057CT.gov Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients | — | Terminated | — | — | — |
NCT05342584CT.gov Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS | — | Recruiting | — | — | — |
NCT07561892CT.gov Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3). | — | Recruiting | — | — | — |
NCT05326516CT.gov A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia | — | Completed | — | — | — |
NCT04817241CT.gov Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients | — | Active Not Recruiting | — | — | — |
NCT05266950CT.gov Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia | — | Withdrawn | — | — | — |
NCT04778397CT.gov Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated | — | Terminated | — | — | — |
NCT04801797CT.gov Venetoclax + Azacitidine vs. Induction Chemotherapy in AML | — | Active Not Recruiting | — | — | — |
NCT04214249CT.gov BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT04659616CT.gov Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT04385290CT.gov Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) | — | Recruiting | — | — | — |
NCT04293562CT.gov A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations | — | Recruiting | — | — | — |
NCT04415008CT.gov Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT04326439CT.gov AflacLL1901 (CHOA-AML) | — | Terminated | — | — | — |
NCT03836209CT.gov Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT03760445CT.gov HDM201 Added to CT in R/R or Newly Diagnosed AML | — | Withdrawn | — | — | — |
NCT03897127CT.gov Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics | — | Active Not Recruiting | — | — | — |
NCT04061239CT.gov Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML | — | Recruiting | — | — | — |
NCT03860844CT.gov Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT03724084CT.gov Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement | — | Terminated | — | — | — |
NCT03701308CT.gov Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy | — | Active Not Recruiting | — | — | — |
NCT03850535CT.gov A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission | — | Terminated | — | — | — |
NCT03591510CT.gov A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML | — | Active Not Recruiting | — | — | — |
NCT03900949CT.gov Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT03709758CT.gov Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML | — | Active Not Recruiting | — | — | — |
NCT03444649CT.gov Epacadostat, Idarubicin and Cytarabine (EIC) in AML | — | Withdrawn | — | — | — |
NCT03258931CT.gov Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML | — | Completed | — | — | — |
NCT03568994CT.gov Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT03563560CT.gov A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT03416179CT.gov A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT03379727CT.gov Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia. | — | Completed | — | — | — |
NCT03298984CT.gov Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML). | — | Completed | — | — | — |
NCT03164057CT.gov A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT03135028CT.gov Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults | — | Terminated | — | — | — |
NCT03053206CT.gov A Prospective, Interventional Study Assessing Response to Cytarabine, Daunorubicin and Etoposide (ADE) for First Relapse of Paediatric Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT03021330CT.gov Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML | — | Active Not Recruiting | — | — | — |
NCT02954653CT.gov A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT03013998CT.gov Study of Biomarker-Based Treatment of Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT02834390CT.gov Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT02724163CT.gov International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia | — | Recruiting | — | — | — |
NCT02198482CT.gov Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | — | Terminated | — | — | — |
NCT02323607CT.gov Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations | — | Completed | — | — | — |
NCT02582359CT.gov MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age | — | Completed | — | — | — |
NCT02632708CT.gov Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | — | Active Not Recruiting | — | — | — |
NCT02521493CT.gov Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome | — | Active Not Recruiting | — | — | — |
NCT02560025CT.gov Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML | — | Completed | — | — | — |
NCT02343939CT.gov Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML) | — | Terminated | — | — | — |
NCT02403310CT.gov A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML | — | Completed | — | — | — |
NCT02236013CT.gov A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02416388CT.gov Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR | — | Recruiting | — | — | — |
NCT02283177CT.gov A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations | — | Completed | — | — | — |
NCT02326584CT.gov A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML | — | Completed | — | — | — |
NCT02272478CT.gov Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations | — | Unknown | — | — | — |
NCT02013648CT.gov Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) | — | Completed | — | — | — |
NCT02140242CT.gov Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML | — | Completed | — | — | — |
NCT02038777CT.gov A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies | — | Completed | — | — | — |
NCT02029950CT.gov Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT01999413CT.gov Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients | — | Completed | — | — | — |
NCT01794169CT.gov Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients With AML | — | Terminated | — | — | — |
NCT01802333CT.gov Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01773408CT.gov A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia | — | Completed | — | — | — |
NCT01696084CT.gov Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01546038CT.gov A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT01477606CT.gov Protocol in Acute Myeloid Leukemia With FLT3-ITD | — | Completed | — | — | — |
NCT01463046CT.gov Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT01455025CT.gov Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT01390337CT.gov A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT01371981CT.gov Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01265199CT.gov Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML) | — | Terminated | — | — | — |
NCT01238211CT.gov Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00943553CT.gov A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects | — | Withdrawn | — | — | — |
NCT00893399CT.gov Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation | — | Completed | — | — | — |
NCT01587430CT.gov 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT01382147CT.gov Evaluation of "Dose-dense Therapy" by S-HAM in Comparison to Conventionally Timed Double Induction in Patients With Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT00915252CT.gov Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT00850382CT.gov Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT00788892CT.gov Trial of CPX-351 in Newly Diagnosed Elderly AML Patients | — | Completed | — | — | — |
NCT00703820CT.gov Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00927498CT.gov A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old | — | Completed | — | — | — |
NCT00093600CT.gov PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00136084CT.gov Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia | — | Completed | — | — | — |
NCT00186966CT.gov Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00589082CT.gov DaunoXome + Ara-C vs Daunorubicin + Ara-C in Elderly AML | — | Completed | — | — | — |
NCT00474006CT.gov High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML | — | Completed | — | — | — |
NCT00005942CT.gov Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy | — | Completed | — | — | — |
NCT00266136CT.gov Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG) | — | Completed | — | — | — |
NCT00209833CT.gov Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T | — | Unknown | — | — | — |
NCT00136448CT.gov High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Daunomycin (this asset) | Shen yang | Approved | BB · 69 |
| Gemtuzumab | M.D. Anderson Cancer Center | P4 | A |
| Amsacrine | University Hospital, Toulouse | P4 | BBB |
| Posaconazole | AstraZeneca | P4 | BBB |
| (+)-Vincristine | Janssen Research & Development, LLC | P3 | BBB |
| Aclacinomycin | Chinese PLA General Hospital | P4 | BB |
| Alvocidib | M.D. Anderson Cancer Center | P2 | BB |
| Prednisone | Children's Oncology Group | P3 | BB |
| Therapeutic Allogeneic Lymphocytes | University of Southern California | P2 | BB |
+42 more in the Acute Myeloid Leukemia cohort
Other indications for Daunomycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia By FAB Classification | — | P3 | BBB · 78 |
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P3 | BBB · 77 |
| Acute Monocytic Leukemia | — | P3 | BBB · 77 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Daunomycin in Acute Myeloid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/daunomycin-acute-myeloid-leukemia-88672
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →